"Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907" by Daniel J. Landsburg

Selected Works of John M. Pagel, MD, PhD

Article

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Blood (2017)

Daniel J. Landsburg, University of Pennsylvania
Rod Ramchandren, Cancer Institute
Yasuhiro Oki, University of Texas MD Anderson Cancer Center
John M. Pagel, Cancer Institute
P.J. Lugtenburg, Erasmus University Rotterdam
Robert Gharavi
Anna Ma
Amir Hafeez
Stefan Klaus Barta, Fox Chase Cancer Center

Link

Disciplines

Medicine and Health Sciences,
Oncology and
Immunology and Infectious Disease

Publication Date

December 7, 2017

Citation Information

Daniel J. Landsburg, Rod Ramchandren, Yasuhiro Oki, John M. Pagel, et al.. "Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907" Blood Vol. 130 (2017) p. 1555 - 1555
Available at: http://works.bepress.com/john-pagel/14/